ORYZON Raises Its Share Capital by EUR 20 Million Through a Private Placement
25 juil. 2019 03h13 HE
|
Oryzon Genomics, S.A.
MADRID, Spain, July 25, 2019 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (MAD: ORY) ("Oryzon" or the "Company"), a clinical‐stage biopharmaceutical company leveraging epigenetics to develop therapies...
ORYZON Presents Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer's Association International Conference in Los Angeles
16 juil. 2019 08h00 HE
|
Oryzon Genomics, S.A.
ETHERAL has recruited more than 100 patients to dateSafety data so far show that vafidemstat is safe and well toleratedParametric functional evolution of the first (blinded) 33 patients that have been...
ORYZON to Present Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer's Association International Conference in Los Angeles
10 juil. 2019 08h00 HE
|
Oryzon Genomics, S.A.
Safety data from the first 90 patients will be presentedParametric evolution of the first (blinded) 33 patients that have been treated for 6 months will also be discussed MADRID, Spain and CAMBRIDGE,...
ORYZON Presents Preliminary Dose Finding Results of Phase II Trial With Iadademstat in AML
14 juin 2019 08h00 HE
|
Oryzon Genomics, S.A.
Results presented at 24th Congress of EHA in AmsterdamCombination of iadademstat and azacitidine shows good safety profile in elderly AML patientsRecommended dose for Phase II established with only...